Researchers led by Dr. Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported dual small-molecule-controlled CRISPR editing systems in Science Translational Medicine. The platforms, PRINCE and Little Prince, turn CRISPR activity on with drug inducers and keep editing largely silent without them. The work addresses a key translational challenge for therapeutic genome editing—controlling where, when, and how strongly editing occurs in living tissues. By using small-molecule switches rather than genetic regulators, the approach targets more practical, potentially reversible control for in vivo applications. The study’s results focus on proof of concept for tight “on/off” behavior in tissue-relevant contexts, positioning the technology for follow-on preclinical work toward safer, more precisely timed gene-editing regimens.